A set of emerging diagnostic tools may help identify breast cancer patients who are most likely to benefit from therapies that target important enzymes fueling a range of subtypes, including BCRA-mutated and triple negative cancers.
from Women's Health News -- ScienceDaily https://ift.tt/2Ei0y10
0 comments:
Post a Comment